Цитокинское гениевое выражение и лечение воздействия на результаты МРТ у иорданских пациентов с множественным склерозом.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khdair Sawsan I, Waleed Mohammed, Hammad Alaa M, Al-Khareisha Lubna, Jaber Tariq, Ayash Majd, Hall Frank Scott
Аннотация
Оригинал публикации
Cytokine Gene Expression and Treatment Impact on MRI Outcomes in Jordanian Patients with Multiple Sclerosis.
BACKGROUND: Central nervous system autoimmune disorders, like multiple sclerosis (MS), are chronic conditions where cytokines contribute significantly to the regulation of inflammation. The diagnosis, progression, and treatment effectiveness of MS are assessed through laboratory tests and clinical evaluation, as well as imaging.
METHOD: This study included 40 healthy individuals as a control group and 75 MS patients, divided into two groups: 45 MS patients receiving fingolimod treatment (MSW) and 30 patients taking other medications (MSOs). Blood samples (3 mL) were collected from all participants, and the mRNA relative expression of cytokine genes (IL-1β, TNF-α, IL-6, and INF-γ) was measured. Additionally, MRI images of MS patients undergoing fingolimod or other treatments were analyzed.
RESULTS: The MSO patient group displayed higher mRNA expressions of IL-1β, TNF-α, IL-6, and INF-γ compared to the control group. Furthermore, TNF-α, IL-6, and INF-γ expressions were elevated in the MSO group compared to the MSW group. MRI scans showed significant improvement in MS patients taking fingolimod compared to those receiving other medications.
CONCLUSIONS: Fingolimod demonstrated greater effectiveness in improving MS patients' conditions, possibly due to its impact on cytokine expression.